Originally scheduled for next week, the meeting of agency advisers will be delayed to give more time for public comment, according to an HHS spokesperson.

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...